Clinical Trial Update: A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment [Phase 3]

View source ↗

Summary

Phase 3 study evaluating LY2216684 as an adjunct to SSRI therapy in adults with major depressive disorder who had only a partial response. The trial was complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• LY2216684

Snippet

Sponsor: Eli Lilly and Company | Conditions: Major Depressive Disorder (MDD) | Phase 3 | Status: COMPLETED | Results posted: 2018-04-24